Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd63 RH5 and MVA RH5 in Tanzanian Adults, Children and Infants
NCT03435874Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Apr 2018
- Primary completion
- Jul 2019
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ChAd63 RH5 and MVA RH5 in Falciparum malaria (PF) (10 arms), sponsored by University of Oxford. Primary endpoints: Solicited symptoms after vaccination at 7 days, Unsolicited symptoms after each vaccination at 28 days and 1 more. Started Apr 2018; status: completed.
02
Drugs
ChAd63 RH5MVA RH5
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on NCT03435874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435874.